EVElena A. Vartanyan

Elena A. Vartanyan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elena A. Vartanyan has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Updating approaches to patient management in the light of new European guidelines on arterial hypertension: analytical review

    by Vera N. Larina, Elena A. Vartanyan, Ekaterina V. Fedorova, Marina P. Mikhaylusova, Olga V. Sayno, Tatiyana N. Mironova

    Data from epidemiological studies show a high prevalence of cardiovascular diseases, including arterial hypertension (AH) and the risk of complications, with changes in AH control and treatment techniques. The review article summarizes the main directions of the new European guidelines on hypertension, which help implement different patient groups in outpatient practice. Secondary risk factors for cardiovascular disease are revised in the new clinical guidelines. The recommendation outlines a diagnostic and therapeutic approach for resistant arterial hypertension, its associated phenotypes, and night-time hypertension. The use and position of renal denervation for antihypertensive treatment have been updated compared with previous recommendations. The new European clinical guidelines reflect a differentiated approach to target indicators of ambulatory blood pressure in different age groups, with functional levels of aging, comorbidity, and AH phenotypes, which is of great clinical importance for a primary care physician and can significantly reduce the risk of heart disease vascular complications.

  • Analysis of the structure of mortality from malignant neoplasms in Moscow in 2019, 2020, and 2021

    by V.N. Larina, E.A. Vartanyan, I.V. Samorodskaya

    Objective. To comparatively analyze mortality from malignant neoplasms (MNs) in Moscow in 2019, 2020, and 2021. Methods. The authors used the Russian Federal State Statistics Service data obtained upon the request of the National Medical Research Center for Therapy and Preventive Medicine on the number of deaths in accordance with the Brief Death Cause Nomenclature (BDCN) by the Russian Federal State Statistics Service and with the average annual population in the one-year age groups in Moscow from 2019 to 2021. The time interval was chosen, by taking into account the indirect evaluation of the impact of the COVID-19 pandemic on mortality rates. Standardized mortality rates (SMRs) were determined. Results. SMRs and the proportion of deaths attributable to MNs of the total number of deaths in Moscow over 2019—2021 amounted to 146.54 (23.5% of SMRs due to all causes) cases per 100.000 population in 2019 and to 131.64 (15.5% of SMRs due to all causes) cases in 2021. An annual decrease in SMRs was noted for 14 of the 34 accounting lines (according to the BDCN). The largest percent into MN mortality is contributed by diseases of the gastrointestinal tract (38.4% in 2019, 40% in 2021), genitourinary (20.8% in 2019, 21.8% in 2021) and respiratory systems (12.5% in 2019, 12.6% in 2021). The largest number of deaths among those from all MNs in 2019-2021 was recorded in tracheal, bronchial, and pulmonary diseases (2.84, 2.34, 1.88% in 2019, 2020, and 2021, respectively). Conclusion. The reduction in MN mortality during the pandemic may be partly related to the problems of determining the original cause of death in COVID-19 concurrent with MNs.


  • Open Access

    Heart failure and atrial fibrillation: updates and perspectives

    by V. N. Larina, I. K. Skiba, A. S. Skiba, V. G. Larin, E. A. Vartanyan

    The article discusses modern approaches and features of management, as well as predicting the risk of complications in patients with cardiac arrhythmias, in particular, atrial fibrillation, and the potential of using conservative and interventional treatment methods for heart failure (HF), taking into account updates and achievements in clinical practice. Epidemiological data, algorithms for managing patients with HF and atrial fibrillation, prevention of thromboembolic events, results of studies comparing the effectiveness of different strategies for atrial fibrillation treatment, catheter ablation compared with drug therapy in patients with HF are presented.


  • Open Access

    Approaches to the Diagnosis and Treatment of Arterial Hypertension in the Light of European Recommendations

    by V. N. Larina, B. Ya. Bart, E. A. Vartanian, E. V. Fedorova, M. P. Mikhailusova, V. I. Lunev

    In this review we present analysis the European recommendations on hypertension – what’s new and what has changed in the tactics of managing patients with arterial hypertension (AH). We compared recommendations on hypertension of the European Society of Cardiology (ESC) and the European Society of hypertension (ESH) 2018 with European recommendations of previous years. In the updated version of guidelines, it is still recommended to determine AH as blood pressure (BP) ≥140 and / or ≥90 mm Hg; to subdivide BP levels into optimal, normal, and high normal, to classify severity of AH as 3 degrees, and to distinguish separately its isolated systolic form. Values for out-of-office BP remained unchanged, but recommendations emerged concerning wider use of ambulatory BP monitoring and self-measurement of BP. For initial therapy, it was recommended to use two drugs combinations preferably as single pill combinations. An increase of the role of nurses and pharmacists in teaching, supporting patients and controlling hypertension has been noted. This can improve the achievement of target BP and, as a result, reduce the cardiovascular risk. New European recommendations highlight the modern aspects of classification and diagnosis of AH, main stages of screening, and algorithm of drug treatment of AH.